Why has NICE said this?
Enzalutamide was recommended for treating metastatic hormone-relapsed prostate cancer in patients who have already had treatment with docetaxel-containing chemotherapy because the benefit to these patients justifies the cost.
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.